Quarterly ResultAug 4, 2026, 04:27 PM
TransMedics Q2 Revenue Up 20.7% to $189.9M; Net Income Down 57.9%
AI Summary
TransMedics Group reported a 20.7% increase in total revenue to $189.9 million for the second quarter of 2026, and a 20.9% increase to $363.9 million for the first six months of 2026. However, net income for Q2 2026 significantly decreased by 57.9% to $14.7 million, with diluted EPS falling to $0.41. The company also saw a 63.7% drop in net income for the first half of the year to $22.0 million. This decline in profitability occurred amidst increased operating expenses, including research, development, and clinical trials, and a substantial increase in finance lease liabilities and property, plant, and equipment related to new facilities.
Key Highlights
- Q2 2026 total revenue increased 20.7% to $189.9 million.
- Q2 2026 net income decreased 57.9% to $14.7 million.
- Q2 2026 diluted EPS was $0.41, down from $0.92.
- H1 2026 total revenue increased 20.9% to $363.9 million.
- H1 2026 net income decreased 63.7% to $22.0 million.
- Cash and restricted cash totaled $491.1 million at June 30, 2026.
- Finance lease right-of-use assets grew to $332.5 million.
- Construction-in-progress rose to $9.8 million for new facilities.
Price Impact
More from TMDX